Access Pharmaceuticals Announces the Commencement of a New AP5346 Clinical Study
24 2월 2006 - 12:37AM
PR Newswire (US)
DALLAS, Feb. 23 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS,
INC. (OTC Pink Sheets: AKCA) announced today the commencement of a
new clinical study involving its DACH platinum polymer therapeutic,
AP5346. The aim of the study, being conducted at the Moores Cancer
Center at the University of California, San Diego in patients with
head and neck cancer under a physician- sponsored IND, is to
demonstrate the ability of the tumor-targeting polymer system to
deliver more platinum to tumors than can be attained with
oxaliplatin, the approved DACH platinum compound. David P.
Nowotnik, Ph.D., Senior Vice President, Research and Development at
Access, commented: "The effectiveness of platinum drugs is believed
to increase as more platinum is delivered to the DNA of tumor
cells. In preclinical studies, we have demonstrated that AP5346
delivers greater than 10-fold more platinum to the tumor DNA than
is achieved by oxaliplatin. The clinical study is designed to
provide us with valuable information on the effectiveness of our
delivery system in man." This clinical study is the first to
commence following the completion of a phase I study in Europe
which demonstrated that AP5346 is well-tolerated, and that it is
active as evidenced by the two partial responses and one stable
disease among the 16 evaluable patients with far advanced disease
in the trial. The results of that study were reported at the
AACR-NCI-EORTC conference in Philadelphia in November. Access
continues to manufacture AP5346 and activate clinical sites in
Europe, and will participate in a phase II trial of the
effectiveness and safety of AP5346 in patients with recurrent,
platinum-sensitive ovarian cancer. Access Pharmaceuticals, Inc. is
an emerging pharmaceutical company developing unique polymer linked
cytotoxics for use in the treatment of cancer. Its lead product
AP5346 is in Phase II clinical testing. The Company also has other
advanced drug delivery technologies including vitamin-mediated
targeted delivery and oral drug delivery. This press release
contains certain statements that are forward-looking within the
meaning of Section 27a of the Securities Act of 1933, as amended,
and that involve risks and uncertainties, including but not limited
to statements made relating to the manufacture and clinical
development of our AP5346 product. These statements are subject to
numerous risks, including but not limited to the risks detailed in
the Company's Annual Report on Form 10-K for the year ended
December 31, 2004, Quarterly Report on Form 10-Q for the quarter
ended September 30, 2005 and other reports filed by us with the
Securities and Exchange Commission. DATASOURCE: Access
Pharmaceuticals, Inc. CONTACT: Stephen B. Thompson, Vice President
& CFO of Access Pharmaceuticals, Inc., +1-214-905-5100; or
investor relations, Donald C. Weinberger of Wolfe Axelrod
Weinberger LLC, +1-212-370-4500, for Access Pharmaceuticals, Inc.
Copyright